- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel's Accelerated Approval Path | 1 | Insider Monkey | ||
| 02.06. | ProKidney beruft Kenneth Locke zum Chief Technical Officer | 2 | Investing.com Deutsch | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 02.06. | ProKidney Appoints Kenneth Locke as Chief Technical Officer | 192 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| 18.05. | ProKidney GAAP EPS of -$0.14 beats by $0.01, revenue of $0.23M beats by $0.03M | 1 | Seeking Alpha | ||
| 15.05. | ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates | 1 | Zacks | ||
| 15.05. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 8 | SEC Filings | ||
| 15.05. | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | 359 | GlobeNewswire (Europe) | On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase... ► Artikel lesen | |
| 25.03. | ProKidney names Greg Madison as chief commercial officer | 2 | Investing.com | ||
| 25.03. | ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer | 270 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney... ► Artikel lesen | |
| 18.03. | BofA reiterates ProKidney stock Underperform rating at $1 target | 2 | Investing.com | ||
| 18.03. | BofA bestätigt "Underperform"-Rating für ProKidney mit Kursziel von 1 US-Dollar | 3 | Investing.com Deutsch | ||
| 18.03. | ProKidney GAAP EPS of -$0.52 beats by $0.18, revenue of $0.89M beats by $0.35M | 1 | Seeking Alpha | ||
| 18.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 18.03. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.03. | PROKIDNEY CORP. - 10-K, Annual Report | 2 | SEC Filings | ||
| 10.11.25 | ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | 336 | GlobeNewswire (Europe) | Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of... ► Artikel lesen | |
| 06.11.25 | ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 | 501 | GlobeNewswire (Europe) | In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral... ► Artikel lesen | |
| 22.09.25 | ProKidney: Hoffnung für Patienten, Chance für Investoren | 542 | sharedeals.de | Die Forschung im Bereich der Nierenerkrankungen entwickelt sich rasant, und neue Therapieansätze rücken in den Fokus von Investoren und Fachwelt. Besonders spannend ist die Frage, ob ProKidney mit seiner... ► Artikel lesen | |
| 12.08.25 | ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | 477 | GlobeNewswire (Europe) | FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,140 | -0,63 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| VALNEVA | 2,236 | -0,97 % | Valneva am Scheideweg: Pfizer-Partnerschaft versus Stellenabbau | ||
| NOVAVAX | 6,660 | -0,15 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,460 | -3,15 % | Heidelberg Pharma: Der Finanzpuffer öffnet ein Zeitfenster | ||
| NANOREPRO | 1,980 | -0,50 % | EQS-News: NanoRepro AG: Jahresabschluss 2025 veröffentlicht - Gruppe mit konsolidiertem Umsatz von rund 16 Mio. EUR auf Wachstumskurs | EQS-News: NanoRepro AG
/ Schlagwort(e): Jahresbericht/Jahresergebnis
NanoRepro AG: Jahresabschluss 2025 veröffentlicht - Gruppe mit konsolidiertem Umsatz von rund 16 Mio. EUR... ► Artikel lesen | |
| VIVOSIM LABS | 0,328 | 0,00 % | VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| OCUGEN | 1,046 | -6,77 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,585 | -0,09 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,194 | -7,42 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,800 | -0,86 % | Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished | ||
| INFLARX | 1,590 | +4,06 % | InflaRx N.V.: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,650 | +1,69 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 39,885 | -1,43 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| GENMAB | 251,70 | -0,47 % | Genmab A/S: Genmab Announces Financial Results for the First Half of 2026 | August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory... ► Artikel lesen | |
| EDITAS MEDICINE | 2,370 | -0,84 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen |
Das Unternehmen PROKIDNEY CORP kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,645 Euro und damit -1,50 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.